Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	29.86
Equity-to-Asset	0.88
Debt-to-Equity	0.01
Debt-to-EBITDA	0.08
Interest Coverage	7.88
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	13.62	Distress Grey Safe
Beneish M-Score	-2.77	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-8.7
	3-Year EBITDA Growth Rate	18.7
	3-Year EPS without NRI Growth Rate	22.2
	3-Year Book Growth Rate	-3.3
	Future 3-5Y EPS without NRI Growth Rate	97.3
	Future 3-5Y Total Revenue Growth Rate	16.41

Momentum Rank

6/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	69.07
	9-Day RSI	67.05
	14-Day RSI	65.89
	6-1 Month Momentum %	34.19
	12-1 Month Momentum %	98.1

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	12.49
	Quick Ratio	11.95
	Cash Ratio	8.87
	Days Inventory	728.74
	Days Sales Outstanding	81.01
	Days Payable	98.16

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-3
	Shareholder Yield %	1.82

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	93.52
	Operating Margin %	11.79
	Net Margin %	29.68
	FCF Margin %	4.46
	ROE %	5.97
	ROA %	5.27
	ROIC %	2.22
	ROC (Joel Greenblatt) %	79.06
	ROCE %	7.28
	Years of Profitability over Past 10-Year	7

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	48.39
	Forward PE Ratio	20.05
	PE Ratio without NRI	22.13
	Shiller PE Ratio	18.78
	Price-to-Owner-Earnings	43.85
	PS Ratio	14.43
	PB Ratio	2.71
	Price-to-Tangible-Book	4.94
	Price-to-Free-Cash-Flow	394.38
	Price-to-Operating-Cash-Flow	28.84
	EV-to-EBIT	34.09
	EV-to-Forward-EBIT	28.34
	EV-to-EBITDA	21.69
	EV-to-Forward-EBITDA	28.34
	EV-to-Revenue	13.67
	EV-to-Forward-Revenue	11.37
	EV-to-FCF	298.93
	Price-to-Projected-FCF	1.93
	Price-to-Median-PS-Value	1.43
	Price-to-Peter-Lynch-Fair-Value	3.16
	Price-to-Graham-Number	2.2
	Price-to-Net-Current-Asset-Value	11.65
	Price-to-Net-Cash	21.5
	Earnings Yield (Greenblatt) %	2.93
	FCF Yield %	0.3
	Forward Rate of Return (Yacktman) %	9.55

Financials (Next Earnings Date:2025-02-27 Est.)

Annual Quarterly TTM

FRA:LGDN's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Ligand Pharmaceuticals Inc Executives

Details

GF Value: €48.33

FRA:LGDN

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with LGDN. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	139.534
	EPS (TTM) (€)	2.288
	Beta	1.22
	Volatility %	42.63
	14-Day RSI	65.89
	14-Day ATR (€)	2.434199
	20-Day SMA (€)	109.925
	12-1 Month Momentum %	98.1
	52-Week Range (€)	53 - 120
	Shares Outstanding (Mil)	18.9

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Ligand Pharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Ligand Pharmaceuticals Inc Stock Events

Financials Calendars

	Event	Date	Price(€)
No Event Data

Ligand Pharmaceuticals Inc Frequently Asked Questions

What is Ligand Pharmaceuticals Inc(FRA:LGDN)'s stock price today?

The current price of FRA:LGDN is €115.00. The 52 week high of FRA:LGDN is €120.00 and 52 week low is €53.00.

When is next earnings date of Ligand Pharmaceuticals Inc(FRA:LGDN)?

The next earnings date of Ligand Pharmaceuticals Inc(FRA:LGDN) is 2025-02-27 Est..

Does Ligand Pharmaceuticals Inc(FRA:LGDN) pay dividends? If so, how much?

Ligand Pharmaceuticals Inc(FRA:LGDN) does not pay dividend.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.